Skip to Main Content

Centessa, a biotech company that raised more than $300 million in an IPO earlier this year, has an early-stage treatment for hemophilia that might compete with the gene therapies nearing the market.

The company’s drug, a monthly treatment injected under the skin, significantly reduced the rate of bleeding for patients with hemophilia A and B in a small study, Centessa said Thursday. In the trial, which enrolled just 23 people and was not placebo-controlled, the highest dose of Centessa’s drug led to an 88% reduction in annualized bleeding rate compared to baseline after six months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment